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Introduction
The increasing bacterial resistance against currently used antibiotics and lack of new antibiotics to combat antimicrobial resistance (AMR) are major challenges to global health and wealth. These major challenges are estimated to cause 10 million deaths every year and $100 trillion in lost productivity to the global economy by 2050. The total syntheses of teixobactin [3] [4] and its analogues [5] [6] [7] and their biological activities have been published in the past year. We 6 and others 5, 7 have reported the synthesis of Arg 10 -teixobactin by replacing the synthetically challenging enduracididine amino acid at position 10 with arginine. We have reported the first structure activity relationships (SAR) of Arg 10 -teixobactin and established the importance D amino acids for antibacterial activity. 4, [6] [7] [8] In previous work, we also elucidated the 3D molecular structures of teixobactin analogues. The disordered structure of teixobactin analogues was found to be vital for their biological activity, D-Gln 4 being essential and D-allo-Ile 5 being important to maintain the disordered structure.
However, the replacement of D-Gln4 and D-allo-Ile 5 with L counterparts provided a more ordered structure of teixobactin. 9 The minimum pharmacophore of teixobactin was reported by Nowick et al. 7 A lysine scan of Arg 10 -teixobactin was reported by the Albericio group. 8 Replacement of any of the four isoleucine residues with lysine led to a complete loss of activity. The L-allo-enduracididine was reported to be important for high antibacterial potency of teixobactin. 3 However, it is also a key bottleneck in the production and development of teixobactin analogues due to various synthetic challenges. 15 We have reported the design and synthesis of potent teixobactin analogues against MRSA through the isosteric replacement of L-allo-enduracididine. 11 Recently, Brimble and coworkers reported the synthesis of teixobactin analogues through replacement of L-allo-enduracididine with amino acid isosteres and evaluated biological activity against MRSA and VRE. 12 To expedite access to highly potent teixobactin analogues, we recently reported a new design by replacing the synthetically challenging enduracididine with commercially available hydrophobic residues such as leucine and isoleucine. 14 Leu 10 -teixobactin and Ile 10 -teixobactin showed identical activity to teixobactin against MRSA in vitro. However, increased hydrophobicity may have an adverse influence on the in vivo capacity to be further developed as therapeutic drugs. Teixobactin and key teixobactin analogues and their antibacterial activities are summarised in figure 1.
Teixobactin has shown antibacterial efficacy in vivo in three mouse models of infection.
Although these results are encouraging, a significant amount of work remains in the development of teixobactin as a therapeutic antibiotic for human use. 15 The translation of molecules from a discovery phase to useful therapeutic antibiotics is prone to high failure due to numerous challenges, such as balancing high efficacy in vivo against a broad spectrum of pathogens with minimal liabilities against human targets and the balancing of hydrophobicity 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 with hydrophilicity to address water solubility issues. 16 There is a pressing need for highly potent analogues of teixobactin to address common drug development challenges. To date, there have been no in vivo evaluation studies of teixobactin analogues.
To address such teixobactin development challenges, we report herein the design and synthesis of 10 highly potent teixobactin analogues ( Figure 2) Results and discussion
Design and synthesis:
To date, teixobactin is the only molecule in its class which has shown in vivo antibacterial efficacy. To realise the therapeutic potential of molecules based on the teixobactin scaffold, there is a pressing need for in vivo ready, simplified teixobactin analogues with ease of access to address the current challenges associated due to the lengthy and daunting total synthesis of teixobactins.
In this work, to address such teixobactin development challenges, we speculated that replacement of Ser 3 , D-Gln 4 and Ala 9 of Leu 10 -teixobactin and Ile 10 -teixobactin with cationic arginine would mimic a suitable balance of hyrophobicity and hydrophilicity similar to natural teixobactin. We thus replaced the Ser 3 , D-Gln 4 and Ala 9 of Leu 10 -teixobactin and Ile 10 -teixobactin with arginine in a systematic fashion (1-10, Figure 2 ). In this way, we realized an optimal balance between hyrophobicity and hydrophilicity. Six of these analogues (1-3, 8-10, Figure 2 ) have a hyrophobic-hydrophilic profile (two positive charges at physiological pH) similar to natural teixobactin. Three analogues (4-6, Figure 2 ) feature three positive charges and one analogue (7, Figure 2 ) bears four positive charges. In total, we synthesised 10 new and highly potent teixobactin analogues ( Figure 2 , 1-10) in a similar fashion to our recently reported highly efficient strategy (scheme 1 and experimental section). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Compound Name MIC* (µg/mL) 1 Arg3-Leu10-texiobactin 0.125 
In vitro antibacterial studies:
The antimicrobial potency of teixobactin analogues 1-10 was assessed against MRSA ATCC 33591. The Leu 10 -teixobactin and natural teixobactin were included as benchmarks for activity. The six analogues 1-3, 8-10 with two cationic charges have hydrophobic-hydrophilic balances similar to natural teixobactin (two cationic charges). These analogues showed comparable potency (MIC 0.125 -0.25µg/ ml) to natural teixobactin (MIC 0.25µg/ ml, Table   1 ). The three analogues 4-6 each possess three cationic charges. Interestingly, analogue 4
showed comparable antimicrobial activity (MIC 0.25µg/ ml) to natural teixobactin. However, analogues 5 and 6 showed 4 times reduced antibacterial activity (MIC 1µg/ ml) than natural teixobactin or Leu 10 -teixobactin. The analogue 7 with four cationic charges also showed reduced antibacterial activity (MIC 1µg/ ml).
The teixobactin analogues 1-10 were further assessed against a panel of antibiotic-resistant and antibiotic susceptible Gram-positive pathogens and comparator antibiotics, daptomycin ( Figure 3 ). The MIC results indicate that the synthetic analogues are potent against the various strains tested, but their MIC distribution differs significantly. Interestingly, we observed a wider distribution of MIC values as the overall net charge of the peptide was increased (Table   1 and 2).
Notably, the MIC values for Staphylococcus were not altered whereas a significant increase in Enterococcus was observed with four cationic charges (7, MIC 2-8µg/ ml). Similar trends have been reported for teixobactin analogues, whereby increases in positive charges give increases in MICs against Staphylococcus aureus ATCC 29213. 13 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 hydrophobic-hydrophilic balance of these analogues was similar to natural teixobactin (two cationic charges). The analogues 4-6 with three cationic charges also showed comparable antibacterial potency to Leu 10 -teixobactin. All synthesized analogues showed good potency against a broad panel of bacteria. The nine analogues 1-6, and 8-10 showed drug like profiles such as high antibacterial potency with optimal balance of hydrophobicity and hydrophilicity.
We have further determined the minimum bactericidal concentrations (MBC) of teixobactin analogues against S. aureus/MRSA strains ( (Table S2) . The teixobactin analogues, daptomycin (labelled as D) was used as the comparator drug. Note the increase in MIC distribution as the overall net charge on the teixobactin analogues was increased. The number in parenthesis indicates the overall net charge of the peptides. Resistance studies and time dependent killing of bacteria using teixobactin analogue 2:
D-Arg 4 -Leu 10 -teixobactin (2) was evaluated for single step resistance in S. aureus ATCC 29213 and MRSA ATCC 33591. We were unable to obtain mutants of S. aureus ATCC 29213
or MRSA ATCC 33591 resistant to teixobactin analogue 2 (5x, 10x, 20x MIC). The calculated frequency of resistance to teixobactin analogue 2 was found to be <10 -10 (SI page S17) which is comparable to teixobactin. 2 A lack of resistance in preliminary studies against 2 is promising in the development of drug like molecules against resistant bacteria.
Time-kill kinetics studies of D-Arg 4 -Leu 10 -teixobactin 2 against S. aureus ATCC 29213 was investigated to ascertain if the chemical modifications retained the bactericidal properties.
The exposure of bacterial inoculum to 0.5 µg/ml or 1 µg/ml of compound 2 resulted in ≥ 2 log10 decrease in bacterial viability at 8 h ( Figure S24 ), which is comparable with previous reports of teixobactin analogues and teixobactin.
2, 14
In vitro cytotoxicity studies:
It was important to evaluate the cytotoxicity of compound 2 on mammalian cells prior to in vivo studies. We determined the cytotoxicity of 2 in human lung epithelial cell line A549 and primary dermal fibroblasts (hDFs). Both of these cell culture models are already established for evaluation of cytotoxicity of antimicrobial peptides. [17] [18] An MTS assay indicated that both mammalian cell-types exposed to various concentrations of the peptide retained significant metabolic activity (≥ 80% viability, Figure 4 a,b), even at a concentration that was ~900 times (250 g/ml) higher than the average MIC (0.27 g/ml) values, indicating excellent cell 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 or nocodazole (5 μg/ml dissolved in DMSO) as controls. At the end of the treatment period, metabolic activities of cells were quantified by MTS-based cell viability assay. Data represents mean ± SEM of three independent triplicate experiments, *p>0.05. After 24 h treatment with 2, A549 cells (c) and hDFs (d) were fixed, fluorescently stained with rhodamine-phalloidin (red), alexa fluor 488 conjugated anti-α-tubulin (green) and Hoechst 33342 (blue) and imaged using IN Cell Analyzer 2200 automated microscope.
Representative images of cells treated with 2 (62.5 μg/ml for 24 h) or nocodazole (10 μg/ml, toxicity control) are shown.
In vivo toxicity studies:
We examined the in vivo toxicity of 2 in a rabbit corneal damage model. A 50 µl of 0.3% (w/v) solution was applied topically (4 times/day) to the circularly debrided cornea and reepithelialization was monitored by fluorescein staining. Vehicle alone served as control. Figure 5 shows the decrease in fluorescein staining with time for both control wounds and wounds treated with 2. There was no significant difference in wound closure between PBStreated wounds or wounds treated with 2 ( Figure S25 ). The lack of any delay in the reepithelialization and wound closure for the injured cornea treated with 2 suggests good biocompatibility of the peptide. 22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 92.3±12.5 m and 121.7±3.2 m after 24 h and 48 h post treatment (p.t.), respectively. For the moxifloxacin-treated cornea the mean corneal thickness was 124.2±9.4 m after 24 h p.t. and 140.3±10.3 m after 48 h p.t. These results suggested that peptide 2 treatment resulted in significant decrease in corneal edema after S. aureus infections when compared PBS treated or moxifloxacin-treated groups. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Bacterial enumeration of the corneal tissues harvested after 8 dosages confirmed the in vivo efficacy of peptide 2 (Figure 7b ). All the infected cornea that received PBS treatment contained significant presence of bacteria, varying from 4.7×10 5 -1.3×10 7 CFU/tissue. The mean log 10 CFU/tissue ± standard error of the mean for PBS treated cornea was 6.51±0.27.
Five out of six cornea treated with peptide 2 had detectable bacterial colonies. The mean log 10 CFU/tissue for peptide 2 treated cornea was 3.97±0.19. Four infected corneas treated with moxifloxacin contained detectable bacterial colonies with a mean log 10 CFU/tissue of 3.7±0.24 was observed. These results confirmed that peptide 2 had a similar antibacterial effect as an established antibiotic in decreasing the bacterial bioburden, thus demonstrating its potential as a safe therapeutic for topical applications.
Conclusion
In conclusion, we have designed and synthesized 10 novel analogues of teixobactin through 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 direct correlation between overall net charge and a narrow distribution of MIC values; for example, a wider distribution of MIC results as the overall net charge of the peptide increases.
The teixobactin-based peptide analogue 2 was found non-cytotoxic both in vitro and in vivo.
In a mice model of infectious keratitis, the topical instillation of 2 resulted in >99.0% reduction in bacterial bioburden and the efficacy was comparable to moxifloxacin. Notably, S. aureus is one of the major etiological agents for bacterial keratitis and has been implicated in corneal melt, leading to significant morbidity and vision loss 15, 16 . Furthermore in our keratitis mice models, the synthetic teixobactin-analogue 2 decreased corneal edema (severity) significantly when compared to untreated cornea or moxifloxacin treated cornea.
To the best of our knowledge, this work is the first in vivo demonstration of the excellent therapeutic potential of a teixobactin analogue in attenuating bacterial infections and associated severity. We believe this work represents a significant advancement in the development of in vivo ready simplified teixobactin analogues. Thus, the design of safe and highly potent synthetic peptide analogues of teixobactin presented here will enable the to the resin by adding 3 eq. of the AA, 3 eq. HATU and 6 eq. DIPEA in DMF and shaking for 1.5h at room temperature. (step c) Esterification was performed using 10 eq. of Fmoc-Ile-OH, 10 eq. DIC and 5 mol% DMAP in DCM and shaking the reaction for 2h. This was followed by capping the unreacted alcohol using 10% Ac 2 O/DIPEA in DMF shaking for 30 min and Fmoc was removed using protocol described earlier in step (b). (step d) Fmoc-Leu-OH was coupled using 4 eq. of AA, 4 eq. HATU and 8 eq. DIPEA in DMF and shaking for 1h followed by Fmoc deprotection using 20% piperidine in DMF as described earlier. purified by RP-HPLC using the protocols described in supporting information SII.
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